LignaMed is dedicated to developing breakthrough treatments for severe asthma, organ transplant viability, and fibrosis. Its lead drug compound, LGM1506, is a single isomer synthetic small molecule with a unique mechanism of action proven to Improve asthma based on statistically significant data from its completed phase II NIH grant. The company is on track to achieve key inflection points for two of its programs: severe Asthma, with Phase I studies in man possible in 2024 and ex vivo lung perfusion for human donor lungs, with potential market approval under a drug as device pathway in 2024.
